2022 World Conference on Lung Cancer (ePosters)-EP16.01-031. Association Between Programmed Death Ligand-1 (PD-L1) Expression and Clinicopathological Features in Non-small Cell Lung Cancer (NSCLC)

EP16.01-031. Association Between Programmed Death Ligand-1 (PD-L1) Expression and Clinicopathological Features in Non-small Cell Lung Cancer (NSCLC)

Back to course

Pdf Summary

A study was conducted in Spain to determine the correlation between programmed death ligand-1 (PD-L1) expression and clinicopathological features in non-small cell lung cancer (NSCLC). The study analyzed 274 patients diagnosed with localized or advanced NSCLC between 2014 and 2020. The main objective was to investigate if PD-L1 expression varied depending on stage, histological type, sex, and smoking habit. The secondary objective was to analyze the prognostic role of PD-L1 in terms of Disease Free Survival (DFS), Progression Free Survival (PFS), and Overall Survival (OS).<br /><br />The results showed that there was a statistically significant relationship between positive PD-L1 expression and males, and negative PD-L1 expression and females. However, no significant relationship was found between PD-L1 expression and NSCLC stages or histology.<br /><br />In terms of survival, patients with localized disease and over-expression of PD-L1 had a tendency towards lower survival rates, suggesting a potential role of adjuvant anti PD-1/PD-L1 therapies. However, the differences in DFS and OS were not statistically significant.<br /><br />There was also a trend observed between PD-L1 expression and smoking habit, with PD-L1 tending to be negative in non-smokers and positive in ex-smokers and active smokers. However, this relationship was not statistically significant.<br /><br />In conclusion, this retrospective analysis did not find significant differences in PD-L1 expression based on stage or histology of NSCLC. However, it did observe a significant association between PD-L1 expression and gender, as well as a trend with smoking status. The study also suggested a potential role for adjuvant anti PD-1/PD-L1 therapies in patients with localized disease and PD-L1 over-expression.

Asset Subtitle

Sena Valcárcel González

Meta Tag

Speaker Sena Valcárcel González

Topic Tumour Biology and Biomarkers - Immune Biology & Immunotherapy

Keywords

Spain

PD-L1 expression

NSCLC

clinicopathological features

sex

smoking habit

Disease Free Survival

localized disease

adjuvant anti PD-1/PD-L1 therapies

retrospective analysis